0.1700
-0.0050
(-2.86%)
At close: January 10 at 2:34:43 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
742.0000
11,580.0000
35,380.0000
29,390.0000
42,983.0000
Operating Expense
653,939.0000
498,765.0000
293,659.0000
217,398.0000
153,680.0000
Operating Income
-653,197.0000
-487,185.0000
-258,279.0000
-188,008.0000
-110,697.0000
Net Non Operating Interest Income Expense
84,332.0000
47,179.0000
9,154.0000
917.0000
2,167.0000
Other Income Expense
--
115.0000
--
--
--
Pretax Income
-566,718.0000
-439,891.0000
-249,125.0000
-187,091.0000
-108,530.0000
Tax Provision
343.0000
-3,524.0000
-420.0000
--
-371.0000
Net Income Common Stockholders
-567,061.0000
-436,367.0000
-248,705.0000
-187,091.0000
-110,378.0000
Diluted NI Available to Com Stockholders
-567,061.0000
-436,367.0000
-248,705.0000
-187,091.0000
-110,378.0000
Total Operating Income as Reported
-653,197.0000
-487,185.0000
-258,279.0000
-188,008.0000
-110,697.0000
Total Expenses
653,939.0000
498,765.0000
293,659.0000
217,398.0000
153,680.0000
Net Income from Continuing & Discontinued Operation
-567,061.0000
-436,367.0000
-248,705.0000
-187,091.0000
-108,159.0000
Normalized Income
-570,649.9700
-436,367.0000
-248,705.0000
-187,091.0000
-108,159.0000
Interest Income
84,635.0000
47,482.0000
9,154.0000
929.0000
2,238.0000
Interest Expense
--
303.0000
--
12.0000
71.0000
Net Interest Income
84,332.0000
47,179.0000
9,154.0000
917.0000
2,167.0000
EBIT
-605,600.0000
-439,588.0000
-249,125.0000
-187,079.0000
-108,459.0000
EBITDA
-594,305.0000
-430,279.0000
-239,469.0000
-179,747.0000
-101,914.0000
Reconciled Depreciation
11,295.0000
9,309.0000
9,656.0000
7,332.0000
6,545.0000
Net Income from Continuing Operation Net Minority Interest
-567,061.0000
-436,367.0000
-248,705.0000
-187,091.0000
-108,159.0000
Total Unusual Items Excluding Goodwill
4,543.0000
--
--
--
--
Total Unusual Items
4,543.0000
--
--
--
--
Normalized EBITDA
-598,848.0000
-430,279.0000
-239,469.0000
-179,747.0000
-101,914.0000
Tax Rate for Calcs
0.0002
0.0000
0.0000
--
0.0000
Tax Effect of Unusual Items
954.0300
--
--
--
--
-
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
IUL.F ImmuCell Corporation
4.9200
+0.82%
SPL.AX Starpharma Holdings Limited
0.1150
+4.55%
MGNX MacroGenics, Inc.
3.1800
-5.07%
COCP Cocrystal Pharma, Inc.
2.2100
-7.14%
REVB Revelation Biosciences, Inc.
0.5288
-8.83%
AGIO Agios Pharmaceuticals, Inc.
34.42
-4.12%
OCUL Ocular Therapeutix, Inc.
8.21
-7.44%
IONS Ionis Pharmaceuticals, Inc.
33.46
-1.88%
PALI Palisade Bio, Inc.
1.9100
-4.98%
CRBU Caribou Biosciences, Inc.
1.6400
-4.65%